| Bioactivity | DBIBB is a specific nonlipid agonist of the type 2 G protein coupled receptor for lysophosphatidic acid (LPA2). DBIBB mitigates the gastrointestinal radiation syndrome, increases intestinal crypt survival and enterocyte proliferation, and reduces apoptosis. DBIBB represents a drug candidate capable of mitigating acute radiation syndrome caused by high-dose γ-radiation to the hematopoietic and gastrointestinal system[1]. | ||||||||||||
| Name | DBIBB | ||||||||||||
| CAS | 1569309-92-7 | ||||||||||||
| Formula | C23H20N2O6S | ||||||||||||
| Molar Mass | 452.48 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|